Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | -5.87M | -6.57M | -2.12M | -1.05M | EBIT |
-128.19M | -131.65M | -118.95M | -86.43M | -51.51M | EBITDA |
-128.19M | -120.48M | -107.27M | -83.95M | -90.31M | Net Income Common Stockholders |
-108.79M | -117.50M | -119.42M | -83.95M | -50.41M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
267.35M | 248.19M | 354.89M | 240.19M | 315.33M | Total Assets |
501.20M | 378.88M | 472.94M | 273.90M | 337.65M | Total Debt |
80.27M | 88.34M | 87.18M | 12.46M | 8.92M | Net Debt |
52.40M | 57.30M | 49.69M | -48.36M | -87.77M | Total Liabilities |
93.23M | 105.60M | 100.73M | 22.94M | 16.43M | Stockholders Equity |
407.98M | 273.29M | 372.21M | 250.97M | 321.22M |
Cash Flow | Free Cash Flow | |||
-104.11M | -114.31M | -104.11M | -72.95M | -51.02M | Operating Cash Flow |
-99.70M | -86.16M | -57.00M | -67.93M | -43.51M | Investing Cash Flow |
-129.56M | 79.02M | -184.69M | 32.53M | -210.08M | Financing Cash Flow |
226.08M | 691.00K | 219.01M | 1.20M | 329.82M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $5.28B | 3.75 | -42.72% | 2.86% | 17.70% | 2.03% | |
50 Neutral | $145.18M | ― | -124.10% | ― | 9.22% | 60.01% | |
49 Neutral | $183.12M | ― | -50.77% | ― | ― | -55.32% | |
39 Underperform | $111.76M | ― | -31.94% | ― | ― | 30.76% | |
39 Underperform | $120.81M | ― | -77.09% | ― | ― | -2.29% | |
35 Underperform | $236.91M | ― | -84.70% | ― | ― | 32.58% | |
33 Underperform | $124.77M | ― | -64.48% | ― | ― | -0.42% |
On March 26, 2025, Nkarta announced a significant restructuring plan, including a 34% reduction in its workforce, to streamline operations and focus resources on the development of NKX019 for autoimmune diseases. This strategic move is expected to extend the company’s cash runway into 2029 and ensure financial stability to achieve key clinical milestones, with preliminary data from ongoing trials anticipated in the second half of 2025. The company also announced the transition of its Chief Financial and Business Officer, Alyssa Levin, who will continue as a consultant post-termination, and the appointment of Nadir Mahmood as the new principal financial officer. These changes are part of Nkarta’s efforts to maintain its competitive position in the evolving landscape of cellular therapies for autoimmune diseases.